Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Gross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (IS) (2024 - 2026)

Amphastar Pharmaceuticals has reported Depreciation & Amortization (IS) over the past 2 years, most recently at $14.3 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (IS) rose 6.74% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $56.7 million, up 7.04%, while the annual FY2025 figure was $56.7 million, 7.04% up from the prior year.
  • Depreciation & Amortization (IS) for Q4 2025 was $14.3 million at Amphastar Pharmaceuticals, up from $14.1 million in the prior quarter.
  • Over five years, Depreciation & Amortization (IS) peaked at $14.6 million in Q2 2025 and troughed at $13.0 million in Q1 2024.